TWiV 823: COVID-19 clinical update #86 with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- 115,000 healthcare worker deaths (Stat News)
- Virology features of infection in children (J Inf Dis)
- Antibody tests not for assessing protection (FDA)
- Infections in vaccinated healthcare workers (NEJM)
- Flawed science of antibody testing (JAMA)
- Test-to-stay in school (US News)
- Vaccination and non-COVID mortality risk (MMWR)
- EUA for Moderna booster (FDA)
- Fact sheet for use of casirivimab and imdevimab (FDA)
- Effect of early treatment with fluvoxamine (Lancet)
- Statins and 28-day mortality (J Inf Dis)
- Cognitive function after COVID-19 (JAMA)
- Routine vaccination coverage worldwide (MMWR)
- Letters read on TWiV 823
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]